FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387135986> ?p ?o ?g. }

• W4387135986 abstract "<h3>Introduction/Background</h3> Tinostamustine, a novel alkylating deacetylase inhibitor, improves drug access to cancer cell DNA strands, breaks them and counteracts damage repair. Here we present the safety and efficacy of tinostamustine in a subset of patients with OvCa enrolled to the Phase I/II clinical trial. <h3>Methodology</h3> An open-label trial of tinostamustine in patients ≥18 years with advanced solid tumours, life expectancy >3 months, Eastern Cooperative Oncology Group performance status (ECOG-PS) ≤2. Phase I dose escalation (standard 3+3 design; 60–100mg/m^2) was conducted to define the maximum tolerated dose and recommended Phase II dose (RP2D). In Phase II, objective response rate (complete response [CR] + partial response [PR]), together with the rate of patients with stable disease (SD) ≥4 months’ duration following the RP2D (80mg/m^2 over 60 minutes on Days 1 and 15 of each 4-week treatment cycle) were determined and summarised using descriptive statistics. Two substudies characterised the effects of tinostamustine (60–80mg/m^2) on cardiac repolarisation. <h3>Results</h3> Forty-nine patients with advanced solid tumours (18 OvCa) were enrolled (table 1). In the entire population of patients with advanced solid tumours there were no dose-limiting toxicities observed in Phase I. In Phase II, treatment-related adverse events (TEAEs) considered related to tinostamustine were haematological or gastrointestinal. Serious tinostamustine-related AEs were principally haematological. In the subset with OvCa, a greater proportion of patients experienced tinostamustine-related TEAEs and serious tinostamustine-related AEs compared with the overall patient population. One patient with OvCa experienced a fatal AE of intra-abdominal haemorrhage together with Grade 4 haematological AEs, all considered related to tinostamustine. 1/18 patients with OvCa achieved a CR as best response, 1/18 PR, and 7/18 SD ≥4 months’ duration. 10/18 patients discontinued treatment due to progressive disease. <h3>Conclusion</h3> Tinostamustine demonstrated signals of efficacy with manageable tolerability in patients with OvCa. <h3>Disclosures</h3> <h3>Funding</h3> Mundipharma Research Limited and Purdue Pharma LP." @default.
• W4387135986 created "2023-09-29" @default.
• W4387135986 creator A5003847273 @default.
• W4387135986 creator A5003897511 @default.
• W4387135986 creator A5016367638 @default.
• W4387135986 creator A5026638826 @default.
• W4387135986 creator A5042264441 @default.
• W4387135986 creator A5047344847 @default.
• W4387135986 creator A5053736790 @default.
• W4387135986 creator A5058296074 @default.
• W4387135986 creator A5067053417 @default.
• W4387135986 creator A5078857320 @default.
• W4387135986 date "2023-09-01" @default.
• W4387135986 modified "2023-10-18" @default.
• W4387135986 title "#163 Results from a phase I/II trial of tinostamustine monotherapy in advanced solid tumours (NCT03345485): safety and efficacy in a subset of patients with advanced ovarian cancer (OvCa)" @default.
• W4387135986 doi "https://doi.org/10.1136/ijgc-2023-esgo.526" @default.
• W4387135986 hasPublicationYear "2023" @default.
• W4387135986 type Work @default.
• W4387135986 citedByCount "0" @default.
• W4387135986 crossrefType "proceedings-article" @default.
• W4387135986 hasAuthorship W4387135986A5003847273 @default.
• W4387135986 hasAuthorship W4387135986A5003897511 @default.
• W4387135986 hasAuthorship W4387135986A5016367638 @default.
• W4387135986 hasAuthorship W4387135986A5026638826 @default.
• W4387135986 hasAuthorship W4387135986A5042264441 @default.
• W4387135986 hasAuthorship W4387135986A5047344847 @default.
• W4387135986 hasAuthorship W4387135986A5053736790 @default.
• W4387135986 hasAuthorship W4387135986A5058296074 @default.
• W4387135986 hasAuthorship W4387135986A5067053417 @default.
• W4387135986 hasAuthorship W4387135986A5078857320 @default.
• W4387135986 hasBestOaLocation W43871359861 @default.
• W4387135986 hasConcept C121608353 @default.
• W4387135986 hasConcept C126322002 @default.
• W4387135986 hasConcept C143998085 @default.
• W4387135986 hasConcept C197934379 @default.
• W4387135986 hasConcept C2779984678 @default.
• W4387135986 hasConcept C2780427987 @default.
• W4387135986 hasConcept C2908647359 @default.
• W4387135986 hasConcept C31760486 @default.
• W4387135986 hasConcept C535046627 @default.
• W4387135986 hasConcept C71924100 @default.
• W4387135986 hasConcept C90924648 @default.
• W4387135986 hasConcept C99454951 @default.
• W4387135986 hasConceptScore W4387135986C121608353 @default.
• W4387135986 hasConceptScore W4387135986C126322002 @default.
• W4387135986 hasConceptScore W4387135986C143998085 @default.
• W4387135986 hasConceptScore W4387135986C197934379 @default.
• W4387135986 hasConceptScore W4387135986C2779984678 @default.
• W4387135986 hasConceptScore W4387135986C2780427987 @default.
• W4387135986 hasConceptScore W4387135986C2908647359 @default.
• W4387135986 hasConceptScore W4387135986C31760486 @default.
• W4387135986 hasConceptScore W4387135986C535046627 @default.
• W4387135986 hasConceptScore W4387135986C71924100 @default.
• W4387135986 hasConceptScore W4387135986C90924648 @default.
• W4387135986 hasConceptScore W4387135986C99454951 @default.
• W4387135986 hasLocation W43871359861 @default.
• W4387135986 hasOpenAccess W4387135986 @default.
• W4387135986 hasPrimaryLocation W43871359861 @default.
• W4387135986 hasRelatedWork W2148589524 @default.
• W4387135986 hasRelatedWork W2283252963 @default.
• W4387135986 hasRelatedWork W2406666623 @default.
• W4387135986 hasRelatedWork W2625610083 @default.
• W4387135986 hasRelatedWork W2786173563 @default.
• W4387135986 hasRelatedWork W2807650186 @default.
• W4387135986 hasRelatedWork W3102005587 @default.
• W4387135986 hasRelatedWork W3216602470 @default.
• W4387135986 hasRelatedWork W4210520527 @default.
• W4387135986 hasRelatedWork W4384922324 @default.
• W4387135986 isParatext "false" @default.
• W4387135986 isRetracted "false" @default.
• W4387135986 workType "article" @default.